Sudo raises series B to advance TYK2 inhibitors for MS, psoriasis
Dec. 21, 2023
Sudo Biosciences Inc. has closed a $116 million series B financing, with the funding raised to be used to advance two investigational TYK2 candidates into the clinic in 2024.
